Mr. Dipali Ojha is a member of the Indian Bar Association which recently initiated proceedings against Dr. Soumya Swaminathan Scientific Director of WHO. In his debriefing, Dipali Ojha explains the details of the procedure and what to do next as well as the situation in India. Situation In India, the Ministry of Health has included ivermectin as part of the treatment of Covid19 as early as April 2021 and has confirmed this several times including in its latest recommendation. The Minister of Health therefore did not follow WHO's advice not to use ivermectin. India, after scientific review of existing evidence, followed suit in Senegal which had not followed the WHO opinion on hydroxychloroquine with continuous use in combination with another molecule since March 2020. "We don't blindly follow WHO," said Prof. Moussa Seydi, head of the infectious diseases department at Fann Hospital in Dakar. While several Indian states continue to prescribe ivermectin successfully, WHO chief scientist Soumya Swaminathan tweeted on May 10 that the UN agency advises against using the drug to treat COVID-19 patients except in clinical trials. The tweet included a press release issued by the company that makes the drug, Merck, saying it had found no evidence to support the use of ivermectin in the treatment of COVID-19. Safety and efficacy are important when using any drug for a new indication. @WHO advises against the use of ivermectin for # COVID19 except in clinical trials https: //t.co/dSbDiW5tCW - Soumya Swaminathan (@doctorsoumya) May 10, 2021 The action of Indian Bar The reply from the Indian Bar was direct – a warning before action demanding accountability to the scientific director of 51 pages that takes up the various arguments in favor of ivermectin and above all questions why the scientific director puts in her tweet an old press release of Merck when on March 31, 2021 she herself issued a WHO opinion about ivermectin. This really raises questions. Inflection point in India A few weeks ago a group of Indian lawyers, whose sponsors are not identified at this time, had attacked the decision of the state of Goa to include ivermectin as part of the treatment against Covid19 following the national guidelines. The reasons given in the proceedings were that WHO had not approved the use of ivermectin. The Government of Goa has therefore produced a submission in response thus confirming that the rational of the WHO advice not to use ivermectin is flawed. This brief is based on extensive evidence including the contradictory analysis of the WHO opinion made by the FLCCC of Dr. Pierre Kory. It is therefore a first for a government to take a legal position in favor of early treatment Deputy Secretary (Health) Vikas Gaunekar stated in an affidavit that Various studies conducted in different countries have shown that the drug has a positive effect on the prevention and treatment/cure of patients. The tablets have been shown to be effective in studies conducted in many countries, " he said. Studies and reports approving ivermectin are available on the website ivmmeta.com. Some reports indicate that the analysis of the World Health Organization was erroneous and that the mortality rate was very low in patients who received the tablets for early treatment or prophylaxis (preventive treatment) The decision fell and the Bombay High Court upheld the use of ivermectin after review by a panel of medical experts from the public and private sector on 13 May 2021. In addition to the fact that the Deputy Secretary of Health recognized the effectiveness of ivermectin as a treatment for Covid, medical experts from both the public and private sectors also confirmed this and the High Court ruled in favor of this treatment. It is indeed the recognition of this treatment in a country that has already generalized its use. Dipali Ojha explains all this in detail in this uncompromising debriefing.

I highly suggest your horse grab some from Amazon.